公开(公告)号：US11679133B2

公开(公告)日：2023-06-20

申请号：US15780153

申请日：2016-11-28

Applicant: Kadimastem Ltd. ,  Yeda Research and Development Co. Ltd.

Inventor： Kfir Molakandov ,  Neta Lavon ,  Avital Beck ,  Michel Revel ,  Ofer Elhanani ,  Yoav Soen ,  Michael Walker ,  Arik Hasson

IPC: A61K35/39 ,  C12N5/00 ,  C12N5/071 ,  A61P5/50 ,  A61P3/10

CPC classification number: A61K35/39 ,  A61P3/10 ,  A61P5/50 ,  C12N5/0676 ,  C12N2500/25 ,  C12N2500/34 ,  C12N2500/38 ,  C12N2501/599 ,  C12N2506/02 ,  C12N2506/45

Abstract: The present invention relates to compositions and methods comprising cell surface markers for pluripotent-derived cells, in particular, pancreatic endoderm-type cells, derived from pluripotent stem cells.

公开(公告)号：US20210054334A1

公开(公告)日：2021-02-25

申请号：US16564893

申请日：2019-09-09

Applicant: Kadimastem Ltd.

Inventor： Michal Izrael ,  Michel Revel ,  Arik Hasson ,  Kfir Molakandov ,  Judith Chebath

IPC: C12N5/079 ,  A61K35/30 ,  G01N33/50 ,  C12N5/0793

Abstract: The present invention discloses a method of identifying agents that affect human astrocytes functionality using ex-vivo differentiated pluripotent stem cells (PSC). In addition, the use of human progenitor astrocytes or human astrocytes for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a human subject is also disclosed.

公开(公告)号：US20180230427A1

公开(公告)日：2018-08-16

申请号：US15863016

申请日：2018-01-05

Applicant: Kadimastem Ltd.

Inventor： Michal Izrael ,  Michel Revel ,  Arik Hasson ,  Kfir Molakandov ,  Judith Chebath

IPC: C12N5/079 ,  C12N5/0793 ,  G01N33/50 ,  A61K35/30

CPC classification number: C12N5/0622 ,  A61K35/30 ,  C12N5/0619 ,  C12N2500/25 ,  C12N2500/38 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/385 ,  C12N2502/081 ,  C12N2502/086 ,  C12N2503/02 ,  C12N2503/04 ,  C12N2506/02 ,  C12N2533/32 ,  C12N2533/52 ,  C12N2533/90 ,  G01N33/5058 ,  G01N33/5073 ,  G01N2510/00

Abstract: The present invention discloses a method of identifying agents that affect human astrocytes functionality using ex-vivo differentiated pluripotent stem cells (PSC). In addition, the use of human progenitor astrocytes or human astrocytes for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a human subject is also disclosed.